How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,630 results for

Botulinum Toxin Injection

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness (...) , and Guidelines Last updated: August 22, 2019 Project Number: RC1170-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of injectable botulinum toxin for pelvic floor pain? What is the cost-effectiveness of injectable botulinum toxin for pelvic floor pain? What are the evidence-based guidelines regarding injectable botulinum toxin for pelvic floor pain? Key Message Two systematic reviews and three randomized

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity. (PubMed)

Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity. The therapeutic effects of botulinum neurotoxin (BoNT) are well documented in upper limb spasticity. However, several factors may influence treatment efficacy, including targeting of neuromuscular junctions (NMJs). We examined whether NMJ-targeted BoNT injections were (...) non-inferior, in terms of efficacy, to current injection practices.Open-label prospective evaluator-blinded study.Conducted across 20 medical centres in Denmark, Finland, Norway and Sweden (24 September 2012 to 11 March 2015).Aged ˃18 years with upper limb spasticity (Modified Ashworth Scale [MAS] score of 2 or 3) following stroke or traumatic brain injury, had received ≥2 consecutive BoNT-A treatment cycles (the latest of which was abobotulinumtoxinA [aboBoNT-A]) and needed BoNT-A retreatment

Full Text available with Trip Pro

2019 BMJ open

3. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. (PubMed)

no difference between the two types of botulinum toxin in terms of overall efficacy, with a mean difference of -1.44 (95% CI -3.58 to 0.70) points lower on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) for BtB-treated participants, measured at two to four weeks after injection. The proportion of participants with adverse events was also not different between BtA and BtB (BtB versus BtA risk ratio (RR) 1.40; 95% CI 1.00 to 1.96). However, when compared to BtA, treatment with BtB (...) Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this condition. Botulinum toxin type B (BtB) is an alternative option

Full Text available with Trip Pro

2016 Cochrane

4. Toxins for Health? Botulinum toxin for migraine

for Health? Botulinum toxin for migraine. Clinical Question: What is the efficacy of botulinum toxin for migraine prophylaxis? Bottom Line: Patients with chronic migraine who receive botulinum toxin (example Botox™) have 2 fewer migraine days per month compared to placebo (from 19 days to 11 days with treatment versus 13 days with placebo), with no benefit in episodic migraine. Adverse events include blepharoptosis, muscle weakness, neck/injection site pain and 3% stop treatment due to adverse events (...) Toxins for Health? Botulinum toxin for migraine Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca May 13, 2019 Toxins

2019 Tools for Practice

5. Effect of Local Anesthetic Versus Botulinum Toxin-A Injections for Myofascial Pain Disorders: A Systematic Review and Meta-Analysis

Effect of Local Anesthetic Versus Botulinum Toxin-A Injections for Myofascial Pain Disorders: A Systematic Review and Meta-Analysis Myofascial pain is a chronic pain disorder characterized by the presence of painful localized regions of stiff muscle and/or myofascial trigger points. Intramuscular myofascial trigger point injections are considered first-line treatments for myofascial pain. Common injectates include local anesthetics and botulinum toxin-A (BTX-A). The objective of this systematic (...) review was to compare the effectiveness of local anesthetics and BTX-A on pain intensity in patients with myofascial pain.A comprehensive systematic search of 3 databases, EMBASE, CENTRAL, and Medline was conducted. The search was comprised of words to describe "myofascial pain" and "injections." We performed a meta-analysis comparing local anesthetic and BTX-A injections across these follow-up week periods: 0 (immediately following the injection), 1 to 2, 3 to 4, 5 to 6, 7 to 8, 9 to 10, 11 to 12

2019 EvidenceUpdates

6. Reply to Comment on Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures. Toxins 2018, 10, 18—Quintessential Use of Ultrasound Guidance for Botulinum Toxin Injections (PubMed)

Reply to Comment on Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures. Toxins 2018, 10, 18—Quintessential Use of Ultrasound Guidance for Botulinum Toxin Injections We thank the authors for their detailed letter and salient comments related to our article on Ultrasound Guidance for botulinum toxin (BoNT) injections.[...].

Full Text available with Trip Pro

2018 Toxins

7. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. (PubMed)

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cerebral palsy (CP) is the most common cause of physical disabilities in children in high-income countries. Spasticity is the most common motor disturbance in CP. Botulinum toxin type A (BoNT-A) is considered the first-line treatment for focal spasticity in people with CP.To evaluate the effectiveness and safety of BoNT-A compared to other treatments used in the management of lower limb spasticity (...) in children with CP.We searched CENTRAL, PubMed, four other databases, and two trial registers in October 2018. We also searched the reference lists of relevant studies and reviews and contacted experts in the field. We did not apply any date or language restrictions.Randomised controlled trials of children with CP, aged between birth and 19 years, treated with BoNT-A injections in the lower limb muscles compared to other interventions. The primary outcomes were gait analysis and function. The secondary

2019 Cochrane

8. Does Botulinum Toxin Injection into Masseter Muscles Affect Subcutaneous Thickness? (PubMed)

Does Botulinum Toxin Injection into Masseter Muscles Affect Subcutaneous Thickness? Botulinum toxin (BoNT) is widely used to treat masseter muscle hypertrophy. Changes in the muscle thickness have been found in many studies, but there has been no report on changes in the thickness from the skin surface to the masseter muscle.We aimed to use ultrasonography to measure not only changes in the muscle thickness but also changes in subcutaneous thickness.This study enrolled 20 volunteer patients: 10 (...) were assigned to an experimental group (injected with each side 25 U of botulinum toxin into both masseter muscles) and 10 to a control group (injected with normal saline). The thicknesses were measured before the injection and at 4, 8, and 12 weeks after the injection both at rest and during maximum muscle contraction.The subcutaneous thickness did not differ significantly over time either at rest (P = 0.063) or during maximal contraction (P = 0.392), or between the experimental and control groups

Full Text available with Trip Pro

2018 Aesthetic surgery journal

9. Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study

Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study Botulinum toxin A (BoNT-A) is a novel treatment for chronic lateral epicondylar tendinopathy. Preliminary studies have demonstrated promising results; however, confirmation of the effectiveness of BoNT-A treatment and further assessment of its side effects are required. This study investigated the analgesic effects (...) of BoNT-A in the treatment of chronic lateral epicondylar tendinopathy.This was a phase-III, single-center, randomized, double-blinded, placebo-controlled study including 60 patients with chronic lateral epicondylar tendinopathy that had been resistant to treatment for >6 months. Patients received either a 40-IU injection of BoNT-A or saline solution placebo into the extensor carpi radialis brevis (ECRB) muscle, aided by electromyographic (EMG) stimulation. Follow-up was 3 months. The primary

2018 EvidenceUpdates

10. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. (PubMed)

Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Achalasia is an oesophageal motility disorder, of unknown cause, which results in increased lower oesophageal sphincter (LOS) tone and symptoms of difficulty swallowing. Treatments are aimed at reducing the LOS tone. Current endoscopic therapeutic options include pneumatic dilation (PD) or botulinum toxin (BTX) injection.To undertake a systematic review comparing the efficacy and safety of two (...) endoscopic treatments, PD and intrasphincteric BTX injection, in the treatment of oesophageal achalasia.Trials were initially identified by searching MEDLINE (1966 to August 2008), EMBASE (1980 to September 2008), ISI Web of Science (1955 to September 2008), The Cochrane Library Issue 3, 2008.  Searches in all databases were conducted in October 2005 and updated in September 2008 and April 2014. The Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE, sensitivity

Full Text available with Trip Pro

2014 Cochrane

11. Early Botulinum Toxin Injections in Infants With Musculoskeletal Disorders: A Systematic Review of Safety and Effectiveness

Early Botulinum Toxin Injections in Infants With Musculoskeletal Disorders: A Systematic Review of Safety and Effectiveness To report current evidence regarding the safety of intramuscular botulinum toxin injection (BTI) in children with orthopedic- and neurologic-related musculoskeletal disorders >2 years of age.PubMed, Cochrane Library, and ScienceDirect, Google Scholar, and Web of Science.Two reviewers independently selected studies based on predetermined inclusion criteria.Data relating (...) that could be attributed to the BTI. The rate of mild to moderate adverse events reported varied from 5% to 25%. Results regarding efficacy were preliminary, dependent on the pathology, and limited by the small number of studies and their low levels of evidence.BTI is already widely used as an early treatment for this age group. The safety profile of BTI in infants appears similar to that of older children and risks appear more related to the severity of the pathology and the location of the injections

2018 EvidenceUpdates

12. Bruxism: Are botulinum toxin injections helpful?

Bruxism: Are botulinum toxin injections helpful? Bruxism: Are botulinum toxin injections helpful? - National Elf Service Search National Elf Service Search National Elf Service » » » » Bruxism: Are botulinum toxin injections helpful? Mar 31 2017 Posted by Bruxism had been defined as, a repetitive masticatory muscle activity (RMMA) characterised by clenching or grinding of the teeth and/or by bracing or thrusting of the mandible. It can occur during wakefulness or during sleep. The potential (...) impact of bruxism on the stomatognathic system is of interest to dentists but it is also of interest to clinicians other field including sleep medicine, neurology and psychology. Management involved combination of oral appliances, counselling/ behavioural strategies and centrally acting drugs, with a common target being muscle relaxation. The aim of this review was to assesses the effects of botulinum toxin (BoNT-A) injections in the management of bruxism. Methods Searches were conducted

2017 The Dental Elf

13. [Intragastric injection of botulinum toxin. A real alternative for obesity treatment? A systematic review].

[Intragastric injection of botulinum toxin. A real alternative for obesity treatment? A systematic review]. Obesity is a prevalent disease in our environment, which comorbidities suppose a great challenge to public health. Intragastric injection of botulinum toxin has been used as treatment for obesity, both in humans and animals. It acts by inhibiting gastric emptying and inducing early satiety, consequently reducing intake and finally achieving weight loss.A bibliographic search in PubMed (...) , Scopus and EMBASE databases between 2000 and 2016 was carried out. Articles regarding the physiological basis of the treatment with intragastric injection of botulinum toxin in human were included, as well as interventional studies, randomised or not.A total of 105 articles were found and 10 were chosen according to our inclusion criteria. Of those, only 4 were randomised and 8 lasted between 8 and 24 weeks. In four of the studies, one randomised, a statistically significant weight loss was found

Full Text available with Trip Pro

2017 Nutricion hospitalaria

14. The treatment of dyssynergic defaecation using botulinum toxin type A injection - interventional variations and clinical outcomes

The treatment of dyssynergic defaecation using botulinum toxin type A injection - interventional variations and clinical outcomes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

15. What are the effects of lower limb botulinum toxin A injections on activity, participation and quality of life in ambulant children with cerebral palsy?

What are the effects of lower limb botulinum toxin A injections on activity, participation and quality of life in ambulant children with cerebral palsy? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

16. Botulinum toxin type a injections versus placebo in patients with overactive bladder (OAB) syndrome: a systematic review and meta analysis

Botulinum toxin type a injections versus placebo in patients with overactive bladder (OAB) syndrome: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

17. Efficacy of botulinum toxin injections on the management of primary bruxism: a systematic review and meta-analysis

Efficacy of botulinum toxin injections on the management of primary bruxism: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

18. Botulinum toxins for the prevention of migraine in adults. (PubMed)

and carried out citation searches on key publications. We sent correspondence to major manufacturers of botulinum toxin.Randomised, double-blind, controlled trials of botulinum toxin (any sero-type) injections into the head and neck for prophylaxis of chronic or episodic migraine in adults. Eligible comparators were placebo, alternative prophylactic agent or different dose of botulinum toxin.Two review authors independently selected trials and extracted data. For continuous outcomes we used mean change (...) Botulinum toxins for the prevention of migraine in adults. Migraine occurs in around 15% of adults and is ranked as the seventh most disabling disease amongst all diseases globally. Despite the available treatments many people suffer prolonged and frequent attacks which have a major impact on their quality of life. Chronic migraine is defined as 15 or more days of headache per month, at least eight of those days being migraine. People with episodic migraine have fewer than 15 headache days per

2018 Cochrane

19. Botulinum toxin for motor and phonic tics in Tourette's syndrome. (PubMed)

of whom had a diagnosis of Tourette's syndrome) completed the study; in total, 21 focal motor tics were treated. Although we considered most bias domains to be at low risk of bias, the study recruited a small number of participants with relatively mild tics and provided limited data for our key outcomes. The effects of botulinum toxin injections on tic frequency, measured by videotape or rated subjectively, and on premonitory urge, are uncertain (very low-quality evidence). The quality of evidence (...) for adverse events following botulinum toxin was very low. Nine people had muscle weakness following the injection, which could have led to unblinding of treatment group assignment. No data were available to evaluate whether botulinum injections led to immunoresistance to botulinum.We are uncertain about botulinum toxin effects in the treatment of focal motor and phonic tics in select cases, as we assessed the quality of the evidence as very low. Additional randomised controlled studies are needed

2018 Cochrane

20. The Difference of Treatment Results between Botulinum Toxin A Split Injection Sites and Botulinum Toxin A Non-Split Injection Sites for Hemifacial Spasm. (PubMed)

The Difference of Treatment Results between Botulinum Toxin A Split Injection Sites and Botulinum Toxin A Non-Split Injection Sites for Hemifacial Spasm. To compare hemifacial spasm treatment results between Botulinum toxin A split injection sites and Botulinum toxin A non-split injection sites.Thirty-one hemifacial spasm patients were randomly assigned into the non-split injection sites group (injecting Botulinum toxin A to the zygomaticus major and risorius each) or split injection sites (...) group with the same amount of Botulinum toxin A as the first method (injection Botulinum toxin A to the zygomaticus major and minor and risorius two injections each) The main outcomes are onset of improvement and effective duration of treatment.Fifteen patients were assigned to non-split injection sites group and 16 patients were assigned to split injection sites group. The median onset of improvement in non-split injection sites group and split injection sites group was 4.0 and 4.5 days

2016 Journal of the Medical Association of Thailand = Chotmaihet thangphaet

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>